Roche, Inovio to Develop Prostate Cancer, Hepatitis B Vaccines

Roche will pay Inovio $10 million plus developmental and commercial milestone payments that could reach $412.5M
Sept. 10, 2013

Inovio Pharmaceuticals Inc. could earn more than $400 million through a partnership with Roche Holding AG to develop vaccines that target prostate cancer and hepatitis B. Read the full story

Sign up for our eNewsletters
Get the latest news and updates

Related

Celltrion to buy US biologics manufacturing plant as part of tariff response strategy
‘Cobots’ drive pharma’s shift toward scalable cell therapies
OnTrak Wireless: Total Bearing Health Solution
Sponsored
OnTrak Wireless & UltraTrak Vario Lubricators: Bearing Health Unified
Sponsored